乳酸乳球菌
拟杆菌
基因
人参
生物
生物化学
异源表达
密码子使用偏好性
重组DNA
化学
细菌
遗传学
基因组
病理
替代医学
16S核糖体RNA
医学
乳酸
作者
Ling Li,So‐Yeon Shin,Soojin Lee,Jin Seok Moon,Wan Taek Im,Nam Soo Han
标识
DOI:10.1021/acs.jafc.5b04098
摘要
This study aimed to produce a pharmacologically active minor ginsenoside F2 from the major ginsenosides Rb1 and Rd by using a recombinant Lactococcus lactis strain expressing a heterologous β-glucosidase gene. The nucleotide sequence of the gene (BglPm) was derived from Paenibacillus mucilaginosus and synthesized after codon optimization, and the two genes (unoptimized and optimized) were expressed in L. lactis NZ9000. Codon optimization resulted in reduction of unfavorable codons by 50% and a considerable increase in the expression levels (total activities) of β-glucosidases (0.002 unit/mL, unoptimized; 0.022 unit/mL, optimized). The molecular weight of the enzyme was 52 kDa, and the purified forms of the enzymes could successfully convert Rb1 and Rd into F2. The permeabilized L. lactis expressing BglPm resulted in a high conversion yield (74%) of F2 from the ginseng extract. Utilization of this microbial cell to produce F2 may provide an alternative method to increase the health benefits of Panax ginseng.
科研通智能强力驱动
Strongly Powered by AbleSci AI